Spherix and Fullife Healthcare Sign Supply and License Agreement for D-Tagatose in Nutraceutical Products in India

Spherix and Fullife Healthcare Sign Supply and License Agreement for
D-Tagatose in Nutraceutical Products in India

BETHESDA, Md. and MUMBAI, India, Nov. 15, 2012 (GLOBE NEWSWIRE) -- Spherix
Incorporated (Nasdaq:SPEX) – an innovator in biotechnology for therapy in
diabetes, metabolic syndrome and atherosclerosis, and provider of technical
and regulatory consulting services to food, supplement, biotechnology and
pharmaceutical companies – and Fullife Healthcare Pvt. Ltd. – an
innovation-driven company focused on bringing unique healthcare solutions to
India – today announced the signing of a supply and license agreement for the
use of D-tagatose in nutraceutical products in India.

Under the terms of the agreement, Spherix has granted Fullife an exclusive,
royalty-bearing license in India for use of Spherix's clinical data and
proprietary know-how to support marketing and dosing of the D-tagatose that
Spherix will also be supplying. The D-tagatose will be used in food or
cosmetic products that may provide health benefits in return for a fixed
royalty on gross sales. Spherix will provide bulk D-Tagatose to Fullife and
Fullife will be responsible for all testing and development of products
containing D-Tagatose for sale in India. Financial terms of the agreement were
not disclosed.

"We are delighted to enter into this supply and license agreement with Fullife
Healthcare, a proven leader in innovative pharmaceutical, nutraceutical and
medical diagnostics in India," said Dr. Claire Kruger, Spherix's CEO. "This
agreement opens a new worldwide nutraceutical / dietary supplement opportunity
for Spherix." Dr. Robert Lodder, President of Spherix, noted "Spherix
D-tagatose meets all USP monograph specifications and the company has
approximately 10+ tons available for nearly immediate delivery."

According to Fullife Healthcare, D-tagatose is a versatile compound that can
be formulated in many ways to help patients with metabolic syndrome and
diabetes cope with their condition. Snehal Shah, CEO of Fullife, added that
"D-tagatose first entered the food market a decade ago but the cost was high
compared to other sweeteners. Nutraceuticals and dietary supplements represent
a new, better use for D-tagatose because of its documented benefits."

D-tagatose is a naturally occurring simple sugar that has been tested
successfully as an oral treatment for glycemic control in patients with Type 2
diabetes and other indications. D-tagatose has been recognized by the U.S.
Food and Drug Administration (FDA) as a GRAS (Generally Recognized as Safe)
substance for use in food and beverages since 2001. Structurally, D-tagatose
is a naturally occurring stereoisomer of D-fructose, and resulted from the
application of Spherix's expertise in chiral carbohydrate chemistry to create
L-sugars that would retain their sweetness characteristics without being

Originally developed as a reduced-calorie sugar substitute, D-tagatose is
processed using the same pathways as other sugars, but at a slower rate, thus
blocking the pathways and preventing the stimulation of insulin secretion and
lowering blood glucose levels. D-tagatose passes to the lower intestine,
where it is fermented by bacteria to produce short-chain fatty acids and
carbon dioxide. It is considered a prebiotic, promoting more favorable
microbial flora in the colon.

About Fullife Healthcare

At Fullife we are completely focused on innovative pharmaceutical,
nutraceutical and medical diagnostics that help people live life to the
fullest.We commenced operations in India in 2008 and since then have been
providing novel solutions to our business partners in domestic and
international markets. An extensive network and access to several top pharma
companies in India, Southeast Asia as well as Europe helps us to deliver these
solutions. We are a company comprised of young, passionate and
enterprise-driven people who would like to bring a fresh new perspective to
the business.For our international partners, Fullife provides an end-to-end
gateway for both prescription and OTC products. We provide a complete product
experience from conception and designing to delivery of the finished
product.Visit Fullife on the Internet at http://www.fullife.co.in/about.html

About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company
under the name Biospherics Research.The Company now leverages its scientific
and technical expertise and experience through its two subsidiaries –
Biospherics Incorporated and Spherix Consulting, Inc.Biospherics is dedicated
to developing and licensing/marketing proprietary therapeutic products for
treatment of diabetes, metabolic syndrome and atherosclerosis.Biospherics is
exploring new drugs and combinations for treatment of high triglycerides, a
risk factor for atherosclerosis, myocardial infarction, and stroke.Spherix's
Consulting subsidiary provides scientific and strategic support for suppliers,
manufacturers, distributors and retailers of conventional foods,
biotechnology-derived foods, medical foods, infant formulas, food ingredients,
dietary supplements, food contact substances, pharmaceuticals, medical
devices, consumer products and industrial chemicals and pesticides.For more
information, please visit www.spherix.com.

The Spherix Incorporatedlogo is availableat

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to
provisions of Section 21E of the Securities Exchange Act of 1934.Investors
are cautioned that such statements in this release, including statements
relating to planned clinical study design, regulatory and business strategies,
plans and objectives of management and growth opportunities for existing or
proposed products, constitute forward-looking statements which involve risks
and uncertainties that could cause actual results to differ materially from
those anticipated by the forward-looking statements.The risks and
uncertainties include, without limitation, risks that product candidates may
fail in the clinic or may not be successfully marketed or manufactured, we may
lack financial resources to complete development of our products, the FDA may
interpret the results of studies differently than us, competing products may
be more successful, demand for new pharmaceutical products may decrease, the
biopharmaceutical industry may experience negative market trends, our
continuing efforts to develop products may be unsuccessful, our common stock
could be delisted from the Nasdaq Capital Market, and other risks and
challenges detailed in our filings with the U.S. Securities and Exchange
Commission.Readers are cautioned not to place undue reliance on any
forward-looking statements which speak only as of the date of this release.We
undertake no obligation to publicly release the results of any revisions to
these forward-looking statements that may be made to reflect events or
circumstances that occur after the date of this release or to reflect the
occurrence of unanticipated events.

CONTACT: Investor Relations
         Phone: (301) 897-2564
         Email: info@spherix.com

Spherix Incorporated Logo
Press spacebar to pause and continue. Press esc to stop.